循环A-CDK2复合物的结构揭示了CDK激活的机制
P D Jeffrey1, A A Russo, K Polyak
1Cellular Biochemistry and Biophysics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Nature
|July 27, 1995
概括
人类cyclinA-cyclin-dependent kinase2 (CDK2) -ATP复合物的晶体结构揭示了cyclinA结合如何激活CDK2. 在CDK2中发生的合规变化.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 分子生物学分子生物学
背景情况:
- 循环素依赖激酶 (CDK) 是细胞循环的关键调节者.
- CDK2,与cyclinA复合,在细胞周期进展中起着关键作用.
- 了解CDK2激活的结构基础对于药物开发至关重要.
研究的目的:
- 为了确定人类cyclinA-CDK2-ATP复合物的高分辨率晶体结构.
- 阐明由cyclinA.激活CDK2背后的分子机制.
主要方法:
- 在X射线晶体学.
- 蛋白质的表达和净化过程
- 在2.3A分辨率下进行结构确定.
主要成果:
- 确定了人类cyclinA-CDK2-ATP复合物的晶体结构.
- 赛克林A与CDK2结合,导致PSTAIRE螺旋和T回路的显著构造变化.
- 这些结构变化重新调整了活性部位的残留物,并缓解了固体障碍,从而导致激酶激活.
结论:
- 该结构为CDK2.2的cyclinA介导激活提供了原子水平的见解.
- 这种机制涉及动态形状变化,这对于酶功能至关重要.
- 这些发现有助于理解细胞循环调节,并为治疗干预提供目标.
相关概念视频
Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...


